Actelis Networks Q3 revenue misses on delays in closing Federal deals

Reuters
2025/11/14
<a href="https://laohu8.com/S/ASNS">Actelis Networks</a> Q3 revenue misses on delays in closing Federal deals

Overview

  • Actelis Q3 2025 revenue fell significantly year-over-year, missing analyst expectations

  • Net loss widened in Q3 due to lower sales and consistent operating expenditures

  • Customer bookings nearly doubled sequentially, with a stronger backlog entering Q4

Outlook

  • Actelis expects financial impact from reorganization in Q4 2025 and early 2026

  • Company sees stronger backlog entering Q4, positioning for improved performance

  • Actelis targets 15-20% reduction in operating expenses starting Q4 2025

Result Drivers

  • ORDER GROWTH - Customer bookings nearly doubled sequentially, indicating strong demand and a robust backlog entering Q4

  • REVENUE DECLINE - Q3 revenue impacted by delays in closing Federal deals and non-recurrence of a large 2024 contract

  • CYBERSECURITY EXPANSION - Expanded cybersecurity and software sales contributed to improved gross margins

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$640,000

$1.50 mln (1 Analyst)

Q3 Net Income

-$2 mln

Q3 Adjusted EBITDA

-$1.82 mln

Q3 Operating Expenses

$2.11 mln

Analyst Coverage

  • The one available analyst rating on the shares is "buy"

  • Wall Street's median 12-month price target for Actelis Networks Inc is $4.00, about 89.3% above its November 13 closing price of $0.43

Press Release: ID:nGNXbDJpD1

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10